Develops oral small molecule therapies for rare diseases, focusing on the treatment of hereditary angioedema (HAE).
Pharvaris N.V., headquartered in Leiden, the Netherlands, is a clinical-stage biopharmaceutical company dedicated to advancing therapies for rare diseases. Established in 2015, Pharvaris specializes in the development and commercialization of innovative treatments. The company's lead candidate, PHA121, is a small molecule bradykinin B2-receptor antagonist currently in Phase II clinical trials for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body.
In addition to PHA121, Pharvaris is developing PHVS416, an on-demand soft capsule designed for rapid exposure during acute HAE attacks, which is progressing through Phase 2 clinical trials. The company also focuses on PHVS719, an extended-release prophylactic tablet for HAE patients, currently undergoing Phase 1 clinical trials. Pharvaris operates across the Netherlands, Switzerland, and the United States, leveraging its strategic locations to advance research and development efforts and collaborate with global healthcare partners.
With a commitment to addressing unmet medical needs in rare diseases, Pharvaris continues to expand its pipeline and explore new therapeutic avenues. Through rigorous clinical testing and strategic partnerships, Pharvaris aims to deliver impactful treatments that improve the quality of life for patients affected by HAE and other rare conditions worldwide.